NCT07007533

A Study to Compare and Evaluate the Safety, Tolerability and Pharmacokinetics Between DA-5223 and DA-5223-R in Healthy Adult Subjects

An Open-label, Randomized, Single-dose, Crossover Study to Compare and Evaluate the Safety, Tolerability and Pharmacokinetics Between DA-5223 and DA-5223-R in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 38 (actual)
• Sponsor: Dong-A ST Co., Ltd. · Industry
• Sex: All
• Age: 19 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study will compare and evaluate the safety, tolerability and pharmacokinetics between DA-5223 and DA-5223-R in healthy adult subjects

Conditions

• Healthy Adult

Interventions

Type	Name	Description
DRUG	DA-5223-R	once a day
DRUG	DA-5223	once a day

Timeline

• Start date: 2025-07-04
• Primary completion: 2025-07-17
• Completion: 2025-07-17
• First posted: 2025-06-06
• Last updated: 2025-08-19

Locations

1 site across 1 country: South Korea